LTRN

Lantern Pharma Inc. (LTRN) | Rumor.io

Lantern Pharma

LTRN

Attention (50-day avg)0%

Attention rank (50-day avg)#3,260

Bullish sentiment (50-day avg)64%

Price to earnings ratio-0.69

Market capitalization13.9M

Earnings per share-1.63

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-17.1M

Social

What share of all stock conversation is about LTRN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0.01% +0.01

Sep 23

Lantern Pharma Inc. ($LTRN) has announced plans to present an open-medicine AI growth plan and live platform demo in a webinar.
The company's chart has been in a downtrend for a very long time, with all technicals and moving averages falling.
The 52-week low is a potential target for the stock, according to a recent analysis.

Generated by AI

Sentiment

Of the messages about LTRN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +44.44	87.13% -2
Bearish	0%	0%	0% -44.44	12.87% +2

Bullish· Mar 31

$LTRN is expected to rebound to $3 due to earnings and updated price targets.
$LTRN has the potential to break into higher levels and may reach $3.50, despite a recent sabotage attempt.
$LTRN's stock price increased following the announcement of its fourth-quarter financial results, which exceeded market expectations.

Bearish· Mar 31

The company's financial situation is precarious, with the possibility of dilution within a year and a history of price collapses due to rumors or announcements.
The asset's price has been artificially suppressed, with some attributing the collapse to sabotage attempts or price manipulation by algorithms.
The company's recent financial results and business updates have been disappointing, with some investors expressing frustration and disappointment with the CEO's leadership and the company's overall performance.

Generated by AI

Topics

Of the messages about LTRN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	99.95%
Earnings	—	0%	0%	0.02%
Technical Analysis	—	0%	0%	0.03%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Sep 23

Lantern Pharma Inc. (LTRN) will present its open-medicine AI growth plan and live platform demo in a webinar.
The company has received a USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent, a significant milestone in its cancer treatment development.
LTRN's AI growth plan and platform demo are set to be showcased in a webinar, providing insights into the company's open-medicine approach.

Generated by AI

Community

Of the messages about LTRN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	66.67%	68%	1.13%
Newcomers	0%	33.33%	32%	98.87%

Regulars· Sep 22

Lantern Pharma Secures USPTO Notice of Allowance for LP-284 Treatment Patent in Aggressive B-Cell Lymphomas, a significant development for the company's cancer treatment efforts.
The LP-284 patent is a crucial milestone, bringing Lantern Pharma closer to commercializing its blood cancer treatment, which could have a substantial impact on the market.
Regular participants are closely watching the pre-market activity, with some expressing optimism and others anticipating a potential reaction from major pharmaceutical companies like Novartis or Roche.

Newcomers· Mar 30

Lantern Pharma's stock ($LTRN) is up after the company confirmed that Panna Sharma will continue as President and CEO, dispelling prior rumors of a leadership change.
The company's stock has been impacted by false third-party reports and market manipulation concerns, leading to significant price drops.
Lantern Pharma's financial results for FY 2025 show a slightly positive stock impact, with the company making strategic updates.

Generated by AI

News

Lantern Pharma raises $4M in registered direct offering

23h agoInvesting.com

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development - Slideshow (NASDAQ:LTRN) 2026-09-24

6d agoSeeking Alpha

Lantern Pharma receives patent allowance for LP-284 cancer drug

8d agoInvesting.com

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient NeedsNEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / , one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc.

10d agoYahoo Finance

Lantern Pharma Q2 2026 Earnings Call: Complete Transcript

11d agoBenzinga

Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap

Detailed price information for Bayerische Motoren Werke ADR (BMWYY) from The Globe and Mail including charting and trades.

12d agoThe Globe and Mail

Also Discussed

Investors talking about LTRN also mention

#	Name	Attention
1	Dyadic International, Inc.DYAI	0%0
2	Peapods FinancePEAS	0%new
3	Terra Luna ClassicLUNC	0.03%-0.08
4	Lottery.com Inc WarrantsLTRYW	0%new
5	TerraClassicUSDUSTC	0%-0.01
6	Silynxcom Ltd.SYNX	0%0
7	VolitionRx LimitedVNRX	0%new
8	Strawberry Fields REIT, Inc.STRW	0%new
9	Lifezone Metals Ltd.LZM	0%new
10	Globavend Holdings LimitedGVH	0%0

Lantern Pharma Inc.

Healthcare
Biotechnology

Lantern Pharma Inc. is a clinical-stage biotechnology company focused on oncology drug discovery and development. Lantern Pharma uses artificial intelligence, machine learning, and genomic data through its proprietary RADR platform to identify precision cancer therapies and match them with the patient groups most likely to benefit. Its current portfolio includes multiple lead drug candidates and an antibody-drug conjugate program spanning several cancer indications, including solid tumors, blood cancers, and rare oncology settings. The company’s work centers on accelerating the development of targeted cancer treatments and improving the efficiency of clinical research through data-driven drug design and patient selection. Lantern Pharma Inc. is based in Dallas, Texas, and operates at the intersection of biotechnology, computational biology, and precision medicine.

Website

Location

1920 McKinney Avenue

Dallas, TX, 75201

United States

Social

What share of all stock conversation is about LTRN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0.01% +0.01

Sep 23

Lantern Pharma Inc. ($LTRN) has announced plans to present an open-medicine AI growth plan and live platform demo in a webinar.
The company's chart has been in a downtrend for a very long time, with all technicals and moving averages falling.
The 52-week low is a potential target for the stock, according to a recent analysis.

Generated by AI

Sentiment

Of the messages about LTRN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +44.44	87.13% -2
Bearish	0%	0%	0% -44.44	12.87% +2

Bullish· Mar 31

$LTRN is expected to rebound to $3 due to earnings and updated price targets.
$LTRN has the potential to break into higher levels and may reach $3.50, despite a recent sabotage attempt.
$LTRN's stock price increased following the announcement of its fourth-quarter financial results, which exceeded market expectations.

Bearish· Mar 31

The company's financial situation is precarious, with the possibility of dilution within a year and a history of price collapses due to rumors or announcements.
The asset's price has been artificially suppressed, with some attributing the collapse to sabotage attempts or price manipulation by algorithms.
The company's recent financial results and business updates have been disappointing, with some investors expressing frustration and disappointment with the CEO's leadership and the company's overall performance.

Generated by AI

Topics

Of the messages about LTRN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	99.95%
Earnings	—	0%	0%	0.02%
Technical Analysis	—	0%	0%	0.03%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Sep 23

Lantern Pharma Inc. (LTRN) will present its open-medicine AI growth plan and live platform demo in a webinar.
The company has received a USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent, a significant milestone in its cancer treatment development.
LTRN's AI growth plan and platform demo are set to be showcased in a webinar, providing insights into the company's open-medicine approach.

Generated by AI

Community

Of the messages about LTRN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	66.67%	68%	1.13%
Newcomers	0%	33.33%	32%	98.87%

Regulars· Sep 22

Lantern Pharma Secures USPTO Notice of Allowance for LP-284 Treatment Patent in Aggressive B-Cell Lymphomas, a significant development for the company's cancer treatment efforts.
The LP-284 patent is a crucial milestone, bringing Lantern Pharma closer to commercializing its blood cancer treatment, which could have a substantial impact on the market.
Regular participants are closely watching the pre-market activity, with some expressing optimism and others anticipating a potential reaction from major pharmaceutical companies like Novartis or Roche.

Newcomers· Mar 30

Lantern Pharma's stock ($LTRN) is up after the company confirmed that Panna Sharma will continue as President and CEO, dispelling prior rumors of a leadership change.
The company's stock has been impacted by false third-party reports and market manipulation concerns, leading to significant price drops.
Lantern Pharma's financial results for FY 2025 show a slightly positive stock impact, with the company making strategic updates.

Generated by AI

Lantern Pharma

Social

Sep 23

Bullish· Mar 31

Bearish· Mar 31

Sep 23

Regulars· Sep 22

Newcomers· Mar 30

Lantern Pharma raises $4M in registered direct offering

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development - Slideshow (NASDAQ:LTRN) 2026-09-24

Lantern Pharma receives patent allowance for LP-284 cancer drug

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

Lantern Pharma Q2 2026 Earnings Call: Complete Transcript

Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap

Also Discussed

Lantern Pharma Inc.

Company Information

Location

Lantern Pharma raises $4M in registered direct offering

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development - Slideshow (NASDAQ:LTRN) 2026-09-24

Lantern Pharma receives patent allowance for LP-284 cancer drug

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

Lantern Pharma Q2 2026 Earnings Call: Complete Transcript

Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap

Also Discussed

Social

Sep 23

Bullish· Mar 31

Bearish· Mar 31

Sep 23

Regulars· Sep 22

Newcomers· Mar 30